Abstract
Abstract
Background
Patient-reported outcome (PRO) measures provide valuable evidence in clinical trials; however, poor compliance with PRO measures is a notable and long-standing problem, resulting in missing data that potentially impact the interpretation of trial results. Interactive, patient-centric platforms may increase participants’ motivation to complete PRO measures over the course of a clinical trial. Thus, the aim of this study was to evaluate and optimize the usability of 3 popular consumer technologies—a traditional app-based interface, a chatbot interface, and a speech-operated interface—that may be used to improve user engagement and compliance with PRO measures.
Methods
Participants aged 18–75 years from the general United States population tested the usability of 3 ePRO platforms: a traditional app-based interface using Datacubed Health Platform (Datacubed), a web-based chatbot interface using the Orbita platform, and a speech-operated Alexa interface using an Alexa Skill called “My Daily Wellness.” The usability of these platforms was tested with 2 PRO measures: the EQ-5D-5 L and the SF-12v2 Health Survey (SF-12v2), Daily recall. Using a crossover design, 3 cohorts of participants tested each ePRO platform daily for 1 week. After testing, interviews were conducted regarding the participants’ experience with each platform.
Results
A total of 24 adults participated in the study. The mean age of participants was 45 years (range, 21–71 years), and half were female (n = 12; 50%). Overall, participants prioritized speed, ease of use, and device portability in selecting their preferred platform. The Datacubed app met these criteria and was the preferred platform among most participants (n = 20; 83%). Participants also suggested various modifications to the platforms, such as programmable notifications, adjustable speed, and additional daily reminders.
Conclusions
These data demonstrate the importance of speed, ease of use, and device portability, features that are currently incorporated in the Datacubed app, in ePRO platforms used in future clinical trials. Additionally, the usability of ePRO platforms may be optimized by adding programmable notifications, adjustable speed, and increased daily reminders. The results of this study may be used to enhance the usability and patient centricity of these platforms to improve user compliance and engagement during clinical trials.
Funder
Janssen Research and Development
Publisher
Springer Science and Business Media LLC
Subject
Health Information Management,Health Informatics
Reference34 articles.
1. FDA-NIH Biomarker Working Group. In (2016) BEST (biomarkers, EndpointS, and other Tools) Resource. Food and Drug Administration, National Institutes of Health, Bethesda, MD
2. US Food and Drug Administration. Patient-reported outcome measures: use in medical product development to support labeling claims (2009) https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-reported-outcome-measures-use-medical-product-development-support-labeling-claims. Accessed April 13, 2023
3. European Medicines Agency. Appendix 2 to the guideline on the evaluation of anticancer medicinal products in man: the use of patient-reported outcome (PRO) measures in oncology studies (2016) https://www.ema.europa.eu/en/documents/other/appendix-2-guideline-evaluation-anticancer-medicinal-products-man_en.pdf. Accessed March 17, 2023
4. Mercieca-Bebber R, King MT, Calvert MJ et al (2018) The importance of patient-reported outcomes in clinical trials and strategies for future optimization. Patient Relat Outcome Meas 9:353–367. https://doi.org/10.2147/prom.S156279
5. Mercieca-Bebber R, Friedlander M, Calvert M et al (2017) A systematic evaluation of compliance and reporting of patient-reported outcome endpoints in Ovarian cancer randomised controlled trials: implications for generalisability and clinical practice. J Patient Rep Outcomes 1(1):5. https://doi.org/10.1186/s41687-017-0008-3